Corvus Pharma Com (CRVS) |
|
3.17 -0.07 (-2.16%)
|
03-03 16:09 |
|
Open: |
3.28 |
Pre. Close: |
3.24 |
|
High:
|
3.335 |
Low:
|
3.13 |
|
Volume:
|
821,479 |
Market Cap:
|
120M |
|
|
|
|
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.462 - 3.496 |
3.496 - 3.516 |
|
Low:
|
3.132 - 3.174 |
3.174 - 3.199 |
|
Close:
|
3.192 - 3.26 |
3.26 - 3.301 |
|
Technical analysis |
as of: 2021-03-03 3:26:10 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 5.06  One year: 5.93 |
| Support: |
Support1: 3.13 Support2: 2.60 |
| Resistance: |
Resistance1: 4.34 Resistance2: 5.08 |
| Pivot: |
3.71 |
| Moving Average: |
MA(5): 3.38 MA(20): 3.85
MA(100): 3.95 MA(250): 3.60 |
| MACD: |
MACD(12,26): -0.16 Signal(9): -0.07 |
| Stochastic oscillator: |
%K(14,3): 3.63 %D(3): 5.25 |
| RSI: |
RSI(14): 39.05 |
| 52-week: |
High: 6.88 Low: 1.01 Change(%): -10.7 |
| Average Vol(K): |
3-Month: 82460 10-Days: 227728 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.CRVS has closed above bottom band by 14.2%. Bollinger Bands are 123.9% wider than normal. The large width of the bands suggest high volatility as compared to CRVS's normal range. The bands have been in this wide range for 15 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Mon, 01 Mar 2021
Do Analysts Agree Monday on Corvus Pharmaceuticals Inc (CRVS) Stock's Target Price? - InvestorsObserver
Fri, 26 Feb 2021
Do Traders Think Corvus Pharmaceuticals Inc (CRVS) Can Turn Around Friday? - InvestorsObserver
Thu, 25 Feb 2021
Is Corvus Pharmaceuticals Inc (CRVS) a Smart Choice in Biotechnology Thursday? - InvestorsObserver
Fri, 19 Feb 2021
Corvus Pharma surges after an insider purchase of ~1.3M shares - Seeking Alpha
Wed, 17 Feb 2021
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock - GlobeNewswire
Fri, 12 Feb 2021
How Does Corvus Pharmaceuticals Inc (CRVS) Stock Rank on Wall Street? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
28 |
| Shares Float (M) |
15 |
|
% Held by Insiders
|
4.98 |
|
% Held by Institutions
|
63.75 |
|
Shares Short (K)
|
1,230 |
|
Shares Short P. Month (K)
|
1,240 |
Stock Financials |
|
EPS
|
-1.509 |
|
EPS Est This Year
|
-3.180 |
|
EPS Est Next Year
|
-3.410 |
|
Book Value (p.s.)
|
1.510 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-38.2 |
|
Return on Equity (ttm)
|
-72.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.592 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-35 |
|
Levered Free Cash Flow (M)
|
-19 |
Stock Valuations |
|
PE Ratio
|
-2.13 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.13 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.57 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
